logo
  

TherapeuticsMD To License Its Products To Mayne Pharma

TherapeuticsMD Inc. (TXMD) said that it has entered into agreements to license its products to an affiliate of Australia's Mayne Pharma Group Limited for commercialization in the United States.

TherapeuticsMD will grant Mayne Pharma an exclusive license to commercialize the Company's Imvexxy, Bijuva, and its prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and will assign to Mayne Pharma the company's exclusive license to commercialize Annovera in the United States.

In addition, TXMD will sell to Mayne Pharma certain assets to allow Mayne Pharma to commercialize the Products, including inventory.

As per the terms of the agreements, TherapeuticsMD will receive about $153.1 million in consideration at closing (including about $13.1 million for acquired net working capital), up to about $42.6 million in minimum royalty payments, and up to $30.0 million in additional milestone payments.

The transaction is expected to close at the end of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Consumer Product Safety Commission or CPSC announced recall of thousands of children's Robes made in China and sold exclusively on Amazon.com by various companies. The recalled robes fail to meet the federal flammability standards for children's sleepwear, posing a risk of burn injuries to children. Further, citing the same concerns, Paper Cape children's pajamas manufactured in Peru ... Health services company Cigna Corp. reported Friday higher profit in its fourth quarter reflecting growth in both Evernorth and Cigna Healthcare segments. Adjusted earnings and topline beat market estimates. Looking ahead for fiscal 2023, the company projects adjusted earnings and adjusted revenues to be higher than last year, but below market view. French drug major Sanofi SA reported Friday higher profit in its fourth quarter with strong revenue growth mainly with strong sales of Dupixent. Looking ahead for fiscal 2023, the company projects higher business earnings, but the expected growth is slower than recorded in fiscal 2022. Sanofi shares were losing around 4 percent in the morning trading in Paris as well as in pre-market activity...
RELATED NEWS
Follow RTT